Skip to main content

Peer Review reports

From: The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

Original Submission
7 Jun 2021 Submitted Original manuscript
12 Jul 2021 Reviewed Reviewer Report - Emerson Chen
18 Oct 2021 Reviewed Reviewer Report
16 Nov 2021 Author responded Author comments - Hee Yeon Lee
1 Dec 2021 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 2
16 Nov 2021 Submitted Manuscript version 2
9 Dec 2021 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 3
9 Dec 2021 Submitted Manuscript version 3
24 Dec 2021 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 4
24 Dec 2021 Submitted Manuscript version 4
25 Jan 2022 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 5
25 Jan 2022 Submitted Manuscript version 5
4 Mar 2022 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 6
4 Mar 2022 Submitted Manuscript version 6
4 Apr 2022 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 7
4 Apr 2022 Submitted Manuscript version 7
24 Jun 2022 Author responded Author comments - Hee Yeon Lee
Resubmission - Version 8
24 Jun 2022 Submitted Manuscript version 8
Publishing
29 Jun 2022 Editorially accepted
11 Jul 2022 Article published 10.1186/s12913-022-08279-6

You can find further information about peer review here.

Back to article page